

06

Social Contributions

Accessibility, Affordability and Availability of Medicines
Doctor-Patient Relationships and
Local Empowerment



- 6.1 Accessibility, Affordability and Availability of Medicines
- 6.2 Patient Care and Global Health Empowerment
- 6.3 Social Philanthropy



06

PharmaEssentia has five social action priorities: First, “Accessibility, Affordability and Availability of Medicines” enables patients to easily access the medicines and therapies they need, and enhances treatment accessibility for underserved populations around the world by acquiring marketing authorizations and organizing support programs; second, “Healthcare and Health Promotion” improves the quality of patient services through patient support projects; “Healthcare Resource Empowerment” encompasses exchanges among healthcare professionals and sharing of medical research to strengthen clinical expertise in MPN; “Community Empowerment” offers health promotion activities in rural areas and patient health education; and finally, “Arts and Culture Education” sponsors local cultural organizations to foster public cultural literacy and aesthetic appreciation.

Main Stakeholders



Patients



Healthcare Professionals



Shareholders and Investors



Local Communities



NPOs/NGOs




Achievement Highlights

- ✦ Obtained PV marketing authorizations in Hong Kong, Brazil, and Argentina in 2025; we now cumulatively hold marketing authorizations in more than **50 countries**
- ✦ New drug technology patents and licenses in **20 countries**
- ✦ Cumulative clinical trial patients worldwide: **1,317 patients**
- ✦ **59 patients** benefited from compassionate treatment in 2025
- ✦ PharmaEssentia and Panco jointly hosted **30 seminars** for healthcare professionals and patients
- ✦ Hosted the 8th MPN Asia in Beijing, China, an event attended by 100 important stakeholders from around the globe
- ✦ Social return on investment (SROI) analysis revealed that our telehealth promotion for older adults in rural areas program created **NT\$12.27** of social value for every NT\$1 of investment in 2025
- ✦ Invested more than **NT\$3 million** in arts and culture sponsorships

PharmaEssentia Social Participation Priorities

PharmaEssentia focuses on the research, development, and application of MPN drugs; supports MPN care and global healthcare empowerment; and monitors international and local health and social issues. PharmaEssentia's three main social participation priorities include accessibility, affordability and availability of medicines; patient care and global healthcare empowerment; and public welfare. We participate in domestic and overseas seminars, medical education initiatives, and patient experience-sharing activities, and have long supported patient, social welfare, and arts and culture education organizations as we work to strengthen our presence across multiple regions as a provider of medical education, patient support, and charitable care. We hope to benefit more patients, healthcare professionals, and communities in future through cross-disciplinary collaborations and localized initiatives that enable our professional capabilities to generate broader positive impacts.



6.1 Accessibility, Affordability and Availability of Medicines

Material Topics	Accessibility, Affordability and Availability of Medicines
Significance for PharmaEssentia	The mission of the biopharmaceutical industry is to promote human health and well-being. PharmaEssentia is driven by patient needs and works to meet unsatisfied patient needs through research, development, and innovation. We provide patients with compassionate treatment and opportunities to participate in clinical trials for pre-launch drugs. We work with our overseas subsidiaries and strategic partners to accelerate regulatory approval across different markets to increase drug availability and fair accessibility.
Policies and Commitments	We are committed to providing high-quality medicines to more patients with unmet medical needs through our research, development, and innovation efforts as we work with our supply chain partners to accelerate regulatory approval so we can satisfy the needs of patients requiring treatment. We also conduct cost analyses to demonstrate the cost-effectiveness of Ropeg and to build a foundation for responsible pricing.
Responsible Units	• PharmaEssentia Taiwan and subsidiary marketing departments and medical affairs teams • The Executive Center for Corporate Sustainability Access to Health Care Team is responsible for compiling and managing material sustainability topics
Response Measures and Management Actions	• Research and development: Apart from continuing to work on MPN indications, we used our patented PEGylation technology to develop PEG-GCSF for treating neutropenia, PEG-IL-2 for treating inflammatory and autoimmune diseases, and anti PD-1 for treating solid tumors; we are also jointly developing TCR-T cell therapies with external collaborators • Continue to promote participation in global clinical trials • Continue to promote compassionate treatment worldwide • Continue to obtain marketing authorizations • Continue to attain milestones on various projects, including marketing authorizations, fair access strategies, and other achievements • Improve affordability of new drugs through fair and reasonable prices, pricing strategies, drug delivery, and drug donations
Evaluation Mechanisms	In accordance with Access to Medicine guidelines, we use (1) Number of developed products/clinical trial patients, (2) Number of patients using BESREMi, and (3) Time to obtain marketing authorizations in various countries as indicators to describe how we satisfy unmet medical needs
Targets for 2025	Obtain marketing authorization for Ropeg to treat PV in Canada and Latin American countries

Achievements in 2025	• A total of 1,317 global clinical trial participants • P1101: Annual clinical trial data from our latest DSUR indicates we have 1,298 clinical trial participants. • Long-acting granulocyte-colony stimulating factor (P2203): Annual clinical trial data from our latest DSUR indicates we have 18 clinical trial participants • P1801: Annual clinical trial data from our latest DSUR indicates we have 1 clinical trial participant. • Number of medication users: As of 2025, more than 18,000 patients have benefited from Ropeg, and the cumulative number of diagnoses has exceeded 20,000. • Number of patients that benefited from compassionate treatment in 2025: 59 patients. • Obtained marketing authorizations: In 2025, we obtained marketing authorizations in Hong Kong, Brazil, and Argentina; we now hold marketing authorizations in more than 50 countries. • BESREMi® was recommended as first-line treatment for high- and low-risk PV by US NCCN guidelines, and competing drugs were relegated to later lines of therapy. • PharmaEssentia Korea implemented a global pricing and reimbursement strategy, and secured formal NHI reimbursement listing • Secured conditional NHI coverage in Brazil, enabling PV patients to meet their medical needs. • Completed Applicant Orientation Meeting (AOM) for new ET indication in the US, and applied for marketing authorizations in Taiwan, Japan, and China. • Collaborated with related foundations in China to enable medication access for low-income patients with rare diseases; continued to promote patient support services in Taiwan, the US, Japan, and other regions; and provided medical care and financial assistance to ensure that patients complete the full course of treatment. • Received approval for special import programs in Columbia and Canada. • New drug technology patents and licenses in 20 countries.
Short-Term Targets (1-2 Years)	Obtain marketing authorization for Ropeg to treat PV in Canada and Latin American countries
Mid-Term Targets (3-5 Years)	Obtain marketing authorization for Ropeg to treat ET in Oman, Singapore, Malaysia, and China, and work to strengthen patient and physician knowledge.
Long-Term Targets (More Than 5 Years)	Continue to conduct clinical trials for new Ropeg indications and obtain marketing authorizations across different countries.

1. Provide High-Quality Medicines to More Patients with Unmet Medical Needs

Compassionate Treatment

PharmaEssentia has long focused on MPN treatments. We are guided by our commitment to MPN patients and proactively address accessibility gaps across different markets. In regions where we have not yet received marketing authorization, or for patients who are ineligible for clinical trials, we offer compassionate treatment to patients with severe MPN or other immediately life-threatening conditions

Treatment Program Targets and Care for Underserved Groups

- This program aims to shorten the wait for patients to access newly launched drugs and prioritize care for the following underserved groups:
- Clinically underserved: We provide drugs to patients in critical condition to ease their pain and improve sleep quality, thereby improving quality of life for the patient and their family members.
- Economically disadvantaged: We prioritize support for patients who are ineligible for local social insurance benefits, older adult patients who have no income, or patients from economically disadvantaged households who cannot afford expensive medical fees to realize equity in healthcare.
- Our compassionate treatment program focuses more on older adult patients as we have limited resources; these patients are often both economically and clinically underserved.

Rigorous and Standardized Management Procedures

- PharmaEssentia and subsidiary Panco have established comprehensive standard operating procedures to manage provision and implementation of compassionate treatment.
 - Multi-stage reviews: Each patient must undergo rigorous reviews by regulatory and ethics committees to ensure clinical urgency and compliance with ethical regulations.
 - Transparent implementation procedures: Applications are submitted directly by medical institutions and/or indirectly through designated NGO organizations, and eligible patients are subject to clinical monitoring by a physician following internal company reviews to ensure healthcare quality and legal compliance.

Program Achievements and Social Impacts

- We regard compassionate treatment as an important component of our corporate social responsibilities, so provide free medication to eligible patients. As of year-end 2025, a cumulative total of 59 patients in Taiwan have benefited from our program and received critical life-sustaining treatment.
- We export medications to regions where we have not yet received marketing authorization (such as Canada) through government-led projects, enabling prompt access to MPN medications for patients with urgent need.
- Following submission of physician diagnostic reports, we also provide compassionate treatment to patients with rare blood cancers (EHE, ATL, SM, CTCL) who are unable to achieve stable control of their disease using existing treatments.

Compassionate treatment achievements over the past five years

Year	2021	2022	2023	2024	2025
Medication donated	New-generation long-acting interferon alfa-2b				
Indications	Taiwan: MPN (PV, ET, MF) Korea: ECD	Taiwan: MPN (PV, ET, MF) Korea: ECD	Taiwan: MPN (PV, ET, MF), EHE Singapore and Malaysia: PV	Taiwan: MPN (PV, ET, MF), EHE, ATL, SM, CTCL Malaysia: PV	Taiwan: MPN (PV, ET, MF), EHE, ATL, SM, CTCL
Cumulative number of benefiting patients	40	40	43	54	59

Accelerating Drug Approval

Ropeg obtained its first marketing authorization in 2019 and has since obtained marketing authorizations in more than 50 countries worldwide (as of 2025), including in several European countries, the US, Japan, Korea, Israel, China, Singapore, Malaysia, Brazil, Argentina, and Hong Kong. In 2026, we are working to obtain marketing authorizations in Columbia, Mexico, Canada, and Vietnam. PharmaEssentia continues to expand the global market share of Ropeg by establishing subsidiaries and working with strategic partners to provide new drugs, reduce treatment burdens for rare diseases, and provide benefits for more patients.

PharmaEssentia has also adopted multiple acceleration strategies to fill drug availability gaps across different regions to speed market readiness and enhance healthcare accessibility:

- Priority review channels: If governments or regulatory authorities determine that local MPN treatment options are limited, and therefore are seeking to expand therapeutic choices, we work to obtain priority review to accelerate the regulatory approval process. For example, we obtained priority review in Singapore, which significantly shortened our time to market, and effectively bridged the drug availability gap.
- Government negotiations and special supply programs: Government agencies may proactively engage in technology and supply negotiations with PharmaEssentia to enable special import programs or special approvals (the approach used in Canada) to accelerate the provision of medicines to clinical institutes, bridge medication gaps during periods where there are insufficient medical resources, and reduce treatment burdens on patients with rare diseases.

- Expand into different regions following recognition by authoritative guidelines: Ropeg's clinical value has been affirmed by international authorities. The National Comprehensive Cancer Network (NCCN) Guidelines, widely regarded as the most widely followed clinical practice guidelines in the United States, recommended Ropeg as a first-line treatment option for PV in 2025, and Ropeg has also been included in European Leukemia Net (ELN) Guidelines. Our efforts ensure that patients worldwide can receive care aligned with international standards.
- Marketing authorization portfolio: PharmaEssentia has expanded into the Middle East (United Arab Emirates, Qatar, and Kuwait), Latin America (Brazil, Argentina, Columbia, and Mexico), and Southeast Asia (Vietnam). We aim to promote access to medicine in markets where medical resources are relatively scarce and reduce global health inequality through practical actions. We strive to fulfill our long-term commitment to patient rights and realize our corporate vision of "Better Science, Better Lives" by continuously enhancing healthcare accessibility in countries at different stages of development.

EHE: Epithelioid hemangioendothelioma; ATL: Adult T-cell leukemia/lymphoma; SM: Systemic mastocytosis; CTCL: Cutaneous T-cell lymphoma

NCCN (National Comprehensive Cancer Network) is a nonprofit organization in the US comprised of a coalition of 33 cancer centers, most of which have been designated as Comprehensive Cancer Centers by the National Cancer Institute.

ELN (European Leukemia Net) is a platform composed of members spanning 45 countries, 220 institutions, and involving over 1,000 researchers and clinical personnel. ELN aims to integrate 120 pioneering leukemia clinical trial groups in Europe, along with resources from collaborating institutes, industry sections, and enterprises to jointly promote the importance of leukemia treatments.

Countries where Ropeg has obtained marketing authorization and year of approval over the past six years

Year	Country	Indications
2021	Israel, Korea, US	PV
2022	Macao	PV
2023	Japan, United Arab Emirates, Bahrain, Qatar	PV
2024	China, Singapore, Malaysia, Oman, Kuwait	PV
2025	Brazil, Argentina, Hong Kong	PV
2026	Taiwan	ET

Product Delivery

Product delivery is an important component of ensuring access to medicine. As different countries have different drug packaging and labeling requirements, PharmaEssentia works with local stakeholders in the US, Korea, Japan, Singapore, Malaysia, and other countries; signs contract manufacturing agreements with local GMP-compliant pharmaceutical manufacturers; and establishes delivery contracts with local GDP-compliant pharmaceutical delivery companies to ensure all drug labels adhere to local requirements and to facilitate product delivery. We are also formulating relevant measures to prevent against counterfeit drugs. (Please refer to 2.6 Sustainable Supply Chain Management and 3.2 Drug Quality and Product Safety)

We not only ensure distribution quality at the institutional level, but also extend our commitment into patient homes. We provide guidance on medication storage and self-injections through patient health education, and offer quality-verified (Q-verified) insulation boxes to patients who require them so their medication can be stored at appropriate temperatures during their journey home from the hospital, ensuring safe product use. This approach not only ensures product consistency during transportation, but also realizes our core philosophy of providing "comprehensive life-cycle care" for patients.

Focus on Patient Needs and Provide Comprehensive Support

- PharmaEssentia Taiwan: Patient Support Program

In 2025, PharmaEssentia and the Taiwan Myeloproliferative Neoplasms Association (TMPNA) jointly hosted the World MPN Day Third TMPNA Member Conference, helping patients understand and access MPN resources through keynote presentations and face-to-face discussions with experts. TMPNA was founded in 2021 and has 94 members as of 2025. We hope to expand community networks for MPN patients and their families through related collaborations and promotions.

- Panco: MPN iCare

Panco established the MPN iCare patient health education interactive platform to provide health education to patients and their families. To help physicians better understand MPN and the efficacy of long-acting interferon therapy, we hosted 28 seminars for healthcare professionals and patients in 2025. These events helped participants better understand MPN and treatment options. Patients and family members can engage in online interactions at any time through the health education section of the platform and the official LINE account.

Patient health education seminar



PharmaEssentia USA: Patient Support SOURCE Program

This program is open to current BESREMI® prescription holders, and provides comprehensive support encompassing insurance information, self-pay discount programs, medication guidance, and prescription renewal processes, enhancing convenience for patients who are unable to use our medications due to delayed insurance payments or insufficient insurance coverage. The program also provides medication to uninsured or underinsured patients. Our goal is to ensure a stable supply of PharmaEssentia medications to patients and reduce their financial burdens.

PharmaEssentia
SOURCE
 Your resource for patient support & education

PharmaEssentia Japan: Patient Support Program

PharmaEssentia Japan strengthened its commitment to Japanese patients in 2025 through the “PV Navigator” website, which provides disease education, diagnostic support tools, and information on insurance benefits to help patients reduce financial treatment burdens. PharmaEssentia Japan also operates the “Towards Tomorrow” member platform, which offers a personalized patient support ecosystem. The platform provides consultations on medical fees and operates a patient support hotline that addresses disease and treatment questions; medication guidance is provided by professional nurses.

PharmaEssentia Japan also implemented multiple measures to enhance healthcare accessibility, including medication home delivery services, free consultations on medical fees, and patient support call centers, which reduced patient burdens, improved treatment accessibility, and responded to patient care needs. In 2025, 54 patients and their families in Japan used these services.

PharmaEssentia Japan Towards Tomorrow website



Poster promoting medication home delivery services



2.Responsible Pricing Strategies with Clinical Value and Cost-Effectiveness

Equitable Access to Medicine Strategies: Enhance Product Efficiency

PharmaEssentia considers provision of innovative medicines to be a core priority for meeting patient demands and reducing burdens on medical insurance systems. The clinical value of BESREMi® has been widely recognized by international authorities, and BESREMi® has been included in both Europe and US treatment guidelines. PharmaEssentia completed a comprehensive health economic assessment encompassing cost-effectiveness, cost-utility, and cost-benefit analysis when launching BESREMi® in Europe to determine the drug's impact on overall healthcare costs. We continue to collect relevant data for subsequent health technology assessments (HTAs) that can further validate the clinical value of BESREMi®.

In terms of social insurance benefits, Asia-Pacific markets such as Taiwan, Korea, Japan, and Australia all offer substantial social insurance coverage. PharmaEssentia has currently obtained social insurance reimbursement listings in Taiwan and Japan. In 2025, we also obtained conditional social insurance reimbursement in Korea and Brazil, benefiting more patients.

Orphan Drug Development and Affordability: Fair and Reasonable Pricing

PharmaEssentia has established a professional team which drives new drug development and applies for inclusion in national insurance reimbursement programs. We also invest substantial R&D resources in orphan drug development. Relevant departments implement pricing application process; provide basic drug information, recommended reimbursement price, and reference prices of comparable drugs; and collect required supporting information (such as cost-effectiveness analysis results). Required application documents are approved and signed by relevant regulatory authorities in each country to ensure reasonable pricing. Ropex, the first interferon approved for PV treatment by the US FDA, has been granted orphan drug status and has been listed as first-line treatment by US NCCN guidelines.

Reasonable Pricing Policy

PharmaEssentia prioritizes patient interests when setting drug prices and also considers multiple factors such as R&D costs, number of patients targeted during the patent period, prices of competing products, expected profits, reimbursements from third-party insurance companies, and national health insurance systems. Prices are set based on

ability to afford medical costs, economic development levels, and pharmaceutical costs for each region. We also reference the “WHO Guideline on Country Pharmaceutical Pricing Policies” when establishing fair and reasonable drug prices.

We assess market affordability and sustainability of healthcare systems when implementing pricing mechanisms, and adopt “fair and reasonable pricing” paired with Health Economics and Outcomes Research (HEOR) assessments to validate the clinical and overall healthcare value of our drugs. This approach not only expands clinical use and reduces patient burdens, but also enhances drug accessibility, equity, and long-term sustainability, while helping us build a strong image of social responsibility and maintain sound operations. We select pricing recommendations for proposal to the competent authorities by comparing international drug prices and conducting health technology assessments to simulate financial impacts following inclusion in local medical insurance programs before our drugs enter new markets. These measures help to reduce medical insurance burdens and ensure a smooth launch.

PharmaEssentia process for obtaining fair and reasonable pricing	
Step 1. Tiered Pricing	Implement tiered pricing for sales regions based on levels of national development.
Step 2. Determine whether there are national reimbursements	If yes, move to Step 3.a; if no, move to Step 3.b
Step 3.a. Medication prices determined by national insurance agencies	In regions like Taiwan, medication prices are set according to social insurance pricing principles in consideration of clinical opinions, proof of efficacy, current treatment costs, proposed payment standards, five-year budget plan based on drug prices, financial impact analyses, and pharmacoeconomics analyses to establish medication prices that benefit the maximum number of patients
Step 3.b. Pricing strategy for private health insurance systems	1. Affordability: Set prices based on affordability levels of each country. 2. Economic data: Reference national GDP, private medical insurance costs, and drugs with similar indications 3. Product value analysis: Based on pharmacoeconomics, health technology assessments (HTAs), and other methodologies. 4. Medical contribution assessments: Analyze product benefits and risks for national medical and economic systems.

Note 1: The process shown in this chart applies to PharmaEssentia Taiwan, Panco, PharmaEssentia USA, and PharmaEssentia Japan

Reasonable Evidence-Based Pricing

PharmaEssentia evaluates product impacts on medical costs using health economics methodologies (such as cost-benefit, cost-utility, and cost-effectiveness analyses) to assess the costs associated with BESREMi® versus standard therapies and other competitive innovative products. This approach has been validated in our main markets.

PharmaEssentia actively participates in empowerment programs and key stages along all value chain stages. We established a new drug innovation research center that leverages AI technologies to enhance R&D performance and assisted the US MPN Research Foundation in developing a clinical trial search tool that facilitates patient access to more timely and accurate clinical information. We have launched patient support programs in Taiwan, the US, and Japan which utilize financial assistance mechanisms to enhance patient drug accessibility, and are working to expand these programs to other countries. We have also planned a series of health promotion activities for patients who are already using BESREMi® to extend their treatment times and support them in completing the full course of treatment.

Reasonable Pricing Achievements					
Country	Current conditions				
US	In the US market, PharmaEssentia USA conducted cost-effectiveness analyses from the perspective of US healthcare payers and confirmed greater cost-effectiveness compared to standard treatments.				
Japan	PharmaEssentia Japan analyzed the cost-effectiveness of BESREMi® and submitted the results to the Japanese Ministry of Health, Labour and Welfare to serve as evidence for HTAs, emphasizing that use of BESREMi® is more cost-effective compared to traditional therapies and competing products.				
Korea	Obtained conditional national insurance reimbursement inclusion in 2025				
Brazel					
BESREMi® Average List Prices and Average Net Price Changes					
Item	Description	2022	2023	2024	2025
Annual weighted average price change	Weighted calculation of list price percentage changes for each product in the portfolio compared with the previous year	-	7.46	8.03	7.78
Annual weighted average net price change	Weighted calculation of net price percentage changes for each product in the portfolio compared with the previous year	7.42	5.00	4.16	4.02

3. Global Access to Medicine for Underserved Groups

PharmaEssentia has long supported underserved groups and developed healthcare plans for developing countries to improve access to medicines. According to the World Health Organization, patients with rare diseases account for approximately 0.65~1% of the world's total population, and most suffer from genetic diseases. The small number of patients and dispersed demands increase patient vulnerability within the healthcare system. As the costs required for developing and manufacturing orphan drugs often exceed anticipated market returns, most manufacturers are reluctant to invest in development for these drugs, which further exacerbates the situations of patients with rare diseases. Among these patients, older adults are more likely to be overlooked as they are the “most vulnerable of the vulnerable.” BESREMi® uses innovative technologies to meet the needs of these underserved groups, offering higher safety, longer-lasting efficacy, and greater friendliness for older adults. PharmaEssentia continues to focus on developing innovative orphan drug technologies while providing and committing to healthcare for underserved groups around the world.

Drug Accessibility Promotions and Measures

To enhance drug accessibility for patients with rare diseases worldwide, PharmaEssentia has implemented relevant measures over several stages across multiple countries by implementing special import programs, obtaining marketing authorizations, and establishing local collaborations. In 2025, we obtained marketing authorizations in Brazil, Argentina, and Hong Kong; successfully secured special import approvals in Columbia and Canada; and initiated collaborations with foundations in China to help low-income patients with rare diseases improve their access to medicines, further expanding the global accessibility of our products.

In addition to special import programs and local collaborations, PharmaEssentia also provides training for healthcare professionals in developing countries such as Columbia, Argentina, and Brazil. We facilitate smooth introduction of new drugs for local clinical use by providing direct supplies, patient and physician health education on new drug technologies, and multi-faceted collaborations with local academic research institutions to enhance access to medicines for patients with rare diseases across different countries.

Promote Product Innovations

In addition to obtaining special import approvals in Columbia and Canada, we also licensed our new drug technologies and patents in 20 countries, including Brazil, Columbia, Ecuador, Mexico, Peru, Egypt, Iran, Iraq, Morocco, Syria, Tunisia, Yemen, India, Armenia, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine, and Uzbekistan, enabling local clinical and pharmaceutical sectors to gain access to and gradually implement these applications.

Patient Assistance and Reimbursement

PharmaEssentia proactively works to obtain national insurance reimbursement inclusion in countries where our products have secured marketing authorization to reduce patient burdens. At present, we have successfully secured national insurance reimbursement inclusion in Taiwan, Korea, and Japan, as well as conditional social reimbursement in Korea and Brazil.

6.2 Patient Care and Global Health Empowerment

Material Topics	Doctor-Patient Relationships and Local Empowerment
Significance for PharmaEssentia	PharmaEssentia focuses on patients and works to enhance clinical knowledge of diseases to strengthen doctor-patient relationships and help patients receive appropriate medications. We also use industrial empowerment activities to ensure that more patients can access to high-quality medications
Policies and Commitments	Implement action plans associated with patient health - Utilize multiple channels for reporting adverse drug events to ensure comprehensiveness of safety data and ensure accurate reporting in accordance with regulations - Ensure that patients using PharmaEssentia drugs clearly understand disease characteristics, drug mechanisms of action, and drug efficacy - Promote disease knowledge, provide advice on disease courses, and offer transfer services - Implement patient care and continuous follow-up during treatment course - Promote empowerment of local healthcare and medical industries to expand our external scope of social influence
Responsible Units	- PharmaEssentia and subsidiary marketing departments and medical affairs teams - The Executive Center for Corporate Sustainability Access to Health Care Team is responsible for compiling and managing material sustainability topics
Response Measures and Management Actions	- PharmaEssentia and all subsidiaries actively participate in and share experiences through medical lectures; we also enthusiastically participate in local community activities to promote local empowerment - Our subsidiary Panco established an MPN health education platform where patients can interact with physicians, and worked with TMPNA to host MPN Awareness Day health education lectures and the first TMPNA member conference, supporting health education for patients in Taiwan - PharmaEssentia USA launched the patient support program SOURCE and BESREMi.com - PharmaEssentia Japan launched a patient support program in Japan which includes a website and related supporting activities
Evaluation Mechanisms	- Regular review of all budgets and executions associated with marketing activities and seminars hosted over the year by the marketing departments and medical affairs teams at PharmaEssentia Taiwan and subsidiaries - Regular review of plans and executions for industrial information-sharing activities
Targets for 2025	Taiwan: - Continue to provide the latest health education information - Continue to work with TMPNA on hosting patient health education activities US : - Continue to operate US “SOURCE patient support program” to assist US patients, and also operate a Patient Care Specialist program that provides full support for patient services Japan : - Promote patient support programs to help patients understand their disease and reduce out-of-pocket expenses

Achievements in 2025	Taiwan: - PharmaEssentia and Panco jointly hosted 30 seminars for healthcare professionals and patients - Added 26 interactive health education articles on MPN iCare and interacted with more than 300 patients and family members - Sponsored 3 patient health education seminars organized by TMPNA - Provided individual case management and care to a cumulative total of 101 patients US : - Hosted 6 PV in Focus patient exchange activities - Participated in ASH Foundation Run/Walk event and Blood Cancer United Light the Night Japan : - Multimedia health education content reached 480,000 viewers - Sponsored Tsubasa Fund II, benefiting a cumulative total of 29 patients - Continued to promote patient support programs to help patients understand their disease and reduce out-of-pocket expenses
Short-Term Targets (1-2 Years)	Taiwan: - Continue to provide the latest health education information - Continue to work with TMPNA on hosting patient health education activities US : - Continue to operate US “SOURCE patient support program” to assist US patients, and also operate a Patient Care Specialist program that provides full support for patient services Japan : - Promote patient support programs to help patients understand their disease and reduce out-of-pocket expense
Mid-Term Targets (3-5 Years)	- Continue to work with patient organizations from various countries on joint promotion of BESREMi® and promote related health education activities to strengthen understanding of disease treatment - Continue to expand activity scope and stakeholder engagement into local medical organizations and institutes - Promote patient support programs in countries where BESREMi® has secured marketing authorization and increase global coverage rate - Accelerate R&D of BESREMi® in other MPN disease domains and expand use of BESREMi® to treatment of other diseases - Track international initiatives and issues, and review investable resources and benefits - Help patient organizations in Taiwan connect with international patient organizations to share treatment experiences
Long-Term Targets (More Than 5 Years)	- Obtain marketing authorizations for BESREMi® in more countries around the globe, and establish comprehensive local medical care and community participation measures for rare diseases to make positive contributions toward and exert our influence on global rare disease medical systems, the industry, and society in general - Help patient organizations in Taiwan connect with international patient organizations to share treatment experiences

PharmaEssentia monitors MPN-associated topics and provides long-term health education and healthcare resources to patients, healthcare professionals, and medical experts to help patients and related personnel better understand disease courses while also helping patients obtain complete care and support. We provide health services for all stages of the patient journey, including disease awareness and screening, MPN diagnosis confirmation and treatment, and all-encompassing post-diagnosis patient care as part of our comprehensive services.

1. Patients: Accompanying and Caring for Patients on the MPN Journey

PharmaEssentia accompanies patients through all stages of treatment. We continue to enhance patient understanding of their diseases and treatments through patient associations and patient support programs. Our services include disease awareness and screening, diagnosis confirmation and treatment, and complete patient care cycles. We not only help patients obtain comprehensive medical and healthcare resources, but also share the latest information on MPN medications with medical personnel and healthcare professionals through regular academic seminars to make positive contributions to related communities and patients.

MPN patient journey			
Stage	1. Disease Awareness and Screening	2. Diagnosis Confirmation and Treatment	3. Complete Patient Care Cycle
Support and Empowerment	• Disease knowledge • Understanding of medical specialties • Seeking medical attention and undergoing the ri	• Diagnosis confirmation • Timely treatment • Appropriate medications	• Complete treatment cycle • Progress tracking
Stakeholders	Patients, patient families, medical personnel	Patients, patient families, medical personnel, experts	Patients, patient families, medical personnel

Patient Health Education Activities

PharmaEssentia continues to support patient health education activities in countries where we have obtained marketing authorization. We have established the following online health education websites in accordance with local regulations:

WHAT’S NEXT PV:

One of the main health education websites in the US, which aims to help the public understand disease knowledge and disease risks. We hope this platform can connect patient communities, enable all patients to receive comprehensive physical and mental support during their treatment courses, and facilitate smooth communications with medical personnel.

BESREMi:

Helps patients in the US understand medications and treatments

Case Management and Community Empowerment

To help patient receive comprehensive care, PharmaEssentia has established patient support programs which actively support patient health education activities and case management, implement continued safety monitoring, reduce patient financial burdens, and promote complete treatments. We helped to establish the Taiwan Myeloproliferative Neoplasms Association (TMPNA) in Taiwan, and support the Patient Power Foundation and the MPN Research Foundation in the US.

Key achievements were as follows:

Post-market surveillance:

In countries where BESREMi® has been approved, PharmaEssentia continues to collect safety information which is used for updating DSURs/PSURs and for assessing BESREMi® risks and benefits. So far, none of our products and services have violated health and safety regulations.

Continued sponsorship of TMPNA: We sponsored a total of 3 MPN patient health education lectures in 2025 and supported patient support programs.

MPN iCare: Added 26 interactive health education articles for more than 300 patients and patient family members in 2025.

US Patient Power Foundation:

Provides support for PV patients during treatment and promotes accurate treatment information, conducts patient education and training through online digital programs, facilitates doctor-patient dialogue, and enhances public understanding of comprehensive patient care.

Support for MPN patient organizations and international education activities:

Supports the activities of major patient organizations in North America, including [MPN Research Foundation](#), [Canadian MPN Research Foundation](#), [MPN Advocacy & Education International](#), Patient Power, and PV Reporter; enables online information-sharing and face-to-face activities to enhance patient education and exchanges; disseminates information related to disease diagnosis, treatment targets, and disease course; and helps the MPN community better understand the medical benefits of BESREMi®.

MPN Research Foundation and clinical trial search engine:

We helped to establish the MPN Research Foundation clinical trial search engine which provides matchmaking channels that assist MPN patients and their doctors in finding appropriate clinical trials for subsequent treatment.

Patient case management support:

Case management in Taiwan: Tracks treatment courses and subsequent medication reactions of individual patients for each project. As of 2025, a total of 101 patients have joined the case management and care program.

US drug compliance tracking: If patients discontinue medication use due to adverse reactions, PharmaEssentia will receive discontinuation notifications through specialty pharmacies; these discontinuations are recorded in pharmacovigilance plans for subsequent tracking.

Patient support program (Please refer to 6.1 Accessibility, Affordability and Availability of Medicines)

Compassionate treatment (Please refer to 6.1 Accessibility, Affordability and Availability of Medicines)

Taiwan Myeloproliferative Neoplasms Association (TMPNA)**MPN iCare****2. Medical and Professional Personnel: Clinical Trials and Healthcare Knowledge Exchanges****Clinical Experience Promotion and International Exchanges**

In terms of disease diagnosis and treatment, we organized a wide range of medical education programs in markets where our products have been launched, published research findings in leading medical journals, and supported Taiwanese physicians in participation of international hematology conferences to promote global medical exchanges while contributing to advances in public health. PharmaEssentia actively gathered feedback from stakeholders through seminars and clinical information-sharing activities to better understand diverse perspectives such as Taiwanese physician views on PV treatment goals, improvements in disease awareness among patients and their families, and suggestions on strengthening muscle function through rehabilitation to reduce spontaneous bleeding risks. We also simplified complex scientific and medical information and created patient education and medication guidance materials that are easy for patients, family members, and caregivers to understand, further enhancing patient care quality. Key events in 2025 are summarized below:

- 2025 American Society of Hematology Annual Meeting: Presented progress on PMF research.
- Education and training for medical personnel in the US: PharmaEssentia USA sponsored continuing medical education institutes in offering medical education resources, including the most cutting-edge PV treatment information.
- PharmaEssentia USA hosted the CR&T International Patient Symposium on MPNs and the International Congress On MPNs in 2025.
- PharmaEssentia USA attended the 2025 Society of Hematologic Oncology Annual Meeting, and jointly discussed and shared the latest findings and innovative achievements on treatments for hematologic malignancies with experts from around the world.
- PharmaEssentia USA attended the 2025 J.P. Morgan Healthcare Conference.
- PharmaEssentia USA is a long-term supporter of MPN Advocacy & Education International, and was honored to sponsor the Annual Women & MPN Conference held in New York City on September 26.
- 2025 Japanese Society of Hematology Annual Meeting: Supported 2 Taiwanese physicians in presenting research on Ropeninterferon
- MPN Asia Annual Meeting: PharmaEssentia has sponsored the MPN Asia Annual Meeting since 2016 to promote sustainable health and social inclusion. As of 2025, the MPN Asia Annual Meeting has successfully been hosted 8 times, demonstrating PharmaEssentia's innovations, contributions, and social influence in the MPN rare-disease domain. MPN Asia 2025 was held in Beijing, China, and nearly 100 important stakeholders around the world were in attendance.

- PharmaEssentia co-hosted an academic seminar in Singapore with the Hematology Society of Taiwan, which was attended by nearly 100 stakeholders.
- PharmaEssentia co-hosted an academic seminar in Hong Kong with The University of Hong Kong, which was attended by nearly 80 stakeholders.
- PharmaEssentia sponsored the 2025 Joint Annual Congress of Taiwan Society of Blood and Marrow Transplantation (TBMT) and Hematology Society of Taiwan (HST) to enhance physician knowledge of the latest developments in the MPN field, strengthening clinical understanding of the therapeutic efficacy of long-acting interferon alfa-2b.

Regular seminars/empowerment activities hosted by PharmaEssentia in 2025			
Organizing unit	Activity	Activity aim	Frequency
PharmaEssentia (Taiwan) and Panco Healthcare	MPN Asia Annual Meetin	Enhance understanding of MPN and drug treatment options	Annually
	Joint Annual Congress of Taiwan Society of Blood and Marrow Transplantation (TBMT) and Hematology Society of Taiwan (HST)		Annually
	Regional seminars		Annually
	Hospital seminars		Once every two months
	MPN case manager training	Enhance understanding of MPN and patient care	Annually
	Patient activities	Enhance patient understanding of MPN	Quarterly
PharmaEssentia Japan	BESREMi® online seminar	Promote BESREMi® usage information to enhance understanding of MPN and drug treatment options	Monthly
	Second BESREMi® Multinational Event		Annually
	Collaborated with and participated in various annual meetings of medical societies in Japan, including Japanese Society for Transplantation and Cellular Therapy (JSTCT), Japanese Society on Thrombosis and Hemostasis (JSTH), and Japanese Society of Hematology (JSH)		Annually
PharmaEssentia USA	Hospital seminars, national/state/local seminars	Promote and introduce information on BESREMi® and PV.	On an ad hoc basis

PharmaEssentia USA hosted the CR&T International Patient Symposium on MPNs and the International Congress On MPNs



PharmaEssentia USA sponsored the Annual Women & MPN Conference



J.P. Morgan Healthcare Conference



MPN Patient Symposium



Third TMPNA Member Conference and Health Education Seminar



Empowerment Programs and Community Empowerment

Apart from proactively participating in international academic activities, PharmaEssentia also emphasizes education & training of healthcare professionals and community engagement. In 2025, PharmaEssentia and Panco jointly supported and organized 30 seminars of various scales for healthcare professionals and patients to enhance clinical knowledge on MPN and treatment options. We also hosted patient forums and arranged for physicians to promote information on MPN through the media.

Activit	Participating Personnel	Activity Achievements
TMPNA member conference	Healthcare professionals, patients, and patient families	Enhance MPN knowledge (MPN gene mutation types and treatment outcomes)
Sin-Lau Hospital World Hemophilia Day health education activities		Enhanced patient muscle strength and reduced risks of sudden bleeding through rehabilitation
Patient activities	Healthcare professionals and patients	Enhanced disease management knowledge

PharmaEssentia USA actively works to strengthen MPN patient support and education, and is a long-term sponsor of several leading patient and rare disease organizations, including MPN Advocacy & Education International, MPN Research Foundation, NORD, Cancer Research & Treatment Fund, and The Leukemia & Lymphoma Society (New England Chapter).

In terms of community engagement, PharmaEssentia USA continues to invest in charity events associated with leukemia such as Blood Cancer United's Light the Night event hosted in Boston and ASH Foundation Run/Walk. Our patient initiative team also traveled to Marrakech, Morocco to participate in the MPN Horizons Conference, connect with the global MPN community, gain the latest insights, strengthen collaborations, and improve our patient support initiatives.

PharmaEssentia USA hosted a total of 6 PV in Focus exchange activities across the US, enabling patients to interact directly with multiple experts as well as alleviate stress, thereby strengthening the supportive power of the patient community through sharing and adaptation activities. In addition to patient support programs, PharmaEssentia USA also proactively participated in international medical and industry conferences, including the 2025 Society of Hematologic Oncology Annual Meeting and the J.P. Morgan Healthcare Conference. We continued to strengthen our collaborative network and share innovative achievements with global industrial and academic leaders, demonstrating our commitment and momentum in advancing treatment for blood disorders and enhancing patient well-being.

PharmaEssentia USA participated in ASH Foundation Run/Walk



PharmaEssentia USA attended the MPN Horizons Conference



PharmaEssentia USA participated in Blood Cancer United Light the Night



PharmaEssentia USA hosted PV in Focus activities



In Japan, PharmaEssentia Japan proactively promoted patient education and support measures associated with hematologic diseases, and delivered educational disease information through digital and media channels, strengthening health literacy associated with PV and ET through multiple channels. Our social media patient education promoted reached 480,000 people. We also collaborated with NHK and representative experts to develop patient-oriented educational materials, and leveraged nationally broadcast health programs to enhance disease awareness.

PharmaEssentia Japan empathizes with the burdens patients face during their treatment journeys and supported the "Tsubasa Fund II" financial assistance program, which was specifically established by the NPO Tsubasa for patients just starting PV and ET treatment. A cumulative total of 29 patients have benefited from this program as of 2025. PharmaEssentia Japan also actively promotes patient support programs (please refer to 6.1 Accessibility, Affordability and Availability of Medicines). We work to ensure that patients receive timely and appropriate treatment by combining information dissemination with substantive medical expense assistance, and continue to strengthen our commitment to patient care and medical access.

6.3 Social Philanthropy

PharmaEssentia is focused on patients, older adults, schoolchildren, women, and other minorities in society. Apart from the aforementioned access to MPN medicines and healthcare empowerment, we also use our manpower and financial resources to provide long-term support for many charity activities such as health promotion in rural areas, biodiversity education for schoolchildren, and sponsorships for local classical music activities as we work to build our social influence.

1.Older Adults: Telehealth Promotion Program for Rural Areas to Eliminate Health Disparities

PharmaEssentia continued to collaborate with NPO Digital Humanitarian Association and utilized the WaCare telehealth platform to provide services to communities in Taitung with relatively limited medical resources. In 2025, physicians, physical therapists, occupational therapists, nutritionists, psychologists, sports specialists, and other professional instructors designed online courses customized for older adults. We launched the program at several locations, including the Taitung Second Dementia Care Building, Taimali Dawang Site, Donghe Taiyuan Site, and Taipei Nangang Zhongyan New Village. We prevented and delayed functional decline, improved the accessibility of medical resources in rural areas, and addressed gaps in digital and healthcare access through ICOPE and Mood Thermometer pre- and post-assessments.



Older adults actively participated in courses covering strength and aerobic exercises, Zumba, towel exercises, and dementia prevention



Feedback from participants:

- Taitung Second Dementia Care Building: The courses aligned well with the needs of older adults with cataracts, and the instructors were engaging and professional.
- Taimali Dawang Site: Participants found the dietary health information (such as the information on green lattes) to be novel, practical, and beneficial for gastrointestinal health.
- Donghe Taiyuan Site: The participants thanked the instructor for showing them stretching exercises which relieved lower back pain and discomfort, as these were very helpful for older adults with mobility difficulties.

Achievements of telehealth promotion and charity projects for older adults in rural areas in 2025

Service Target	Stakeholders	Number of Participants	Resources Invested	Activity Description	Achievements
- Taitung Second Dementia Care Building - Taimali Dawang Site - Taitung Donghe Taiyuan Site	- Older adults served by community sites - Health promotion managers - Local caregivers and family members - Medical and health experts (including specialist physicians, therapists, and exercise specialists)	- Taitung Second Dementia Care Building: 8,205 participants - Taimali Dawang Site: 4,747 participants - Donghe Taiyuan Site: 5,965 participants - A total of 18,917 participants	- PharmaEssentia invested NT\$600,000 - Professional team: Comprised of 50% sports specialists, 10.5% occupational therapists, and 7.9% physicians and nurses.	Telehealth promotion courses: As of September 2025, we have hosted a total of 109 telehealth lectures.	- Health literacy enhancement: We organized classes tailored to the mobility capabilities, cognitive capabilities, and emotional issues of older adults, as assessed using ICOPE, effectively enhancing health management and awareness in participants. - Social value: The main positive impacts were helping older adults establish telehealth habits, promoting community cohesion, and reducing caregiver stress through stakeholder engagement. - Carbon reduction benefits: We delivered courses through online instead of in-person channels to reduce carbon emissions generated from travel. - SROI analysis revealed that this program generated NT\$12.27 of social value for every NT\$1 of investment.

2.Schoolchildren: Diverse Educational Experiences for Strengthening Environmental Literacy and Spatial Awareness

Support In-Depth Educational Experiences and Cultivate Biodiversity Awareness

PharmaEssentia worked with Jane Goodall Institute, a non-profit organization, to help elementary school students develop an interest in plants, the environment, and animals, aiming to cultivate green youth leaders and encourage the next generation to protect Earth and the environment.



2025 Biodiversity Hope Box “The World of Plants” Project Achievements					
Service Target	Stakeholders	Number of Participants	Resources Invested	Activity Description	Achievements
• Shipai Elementary School, Beitou District, Taipei • Donghu Elementary School, Linkou District, New Taipei City • Daya Elementary School, Daya District, Taichung City • Sanhe Elementary School, Daya District, Taichung City	• School teachers • Schoolchildren	• A total of 117 teachers and students participated in the course and showcased their achievements	• PharmaEssentia invested NT\$200,000 • Education resources: We provided “Biodiversity Surprise Box” teaching materials and natural dyes (such as cape jasmine fruits) for a hands-on crafting experience	• On-campus courses: We conducted 3 sessions (2 classes per session) at each school, making a total of 6 classes • The course covered four core themes: Connect (Biodiversity Surprise Box), Learn (Uses of Plants and Fruits), Act (Handmade Shadow Puppets), and Celebrate (Performance Showcase).	• Enhanced understanding: 98% of students better understood the importance of plant and animal interdependence after listening to the stories. • Skill mastery: 100% of participants learned how to make and operate shadow puppets. • Strengthened awareness: Helped students understand the “One Health” relationship linking the environment, animals, and human health.

Biodiversity Surprise Box Course and Student Creations



Feedback from teachers: We thank PharmaEssentia for their support and for organizing the Biodiversity Surprise Box course, which helped the students learn through observation, discussion, and hands-on crafting of shadow puppets.

Student feedback: “This course gave me a better understanding of animals and plans, and I also learned how to create a unique shadow puppet show that I performed in front of other students.”

“I was most interested in drawing the butterflies and cutting out their wings. Although it was difficult, I learned a lot and hope to take this course again.”

Partnered with the Taipei Performing Arts Center to Teach Schoolchildren Physical Expression Skills

PharmaEssentia and Taipei Performing Arts Center jointly sponsored a program for promoting arts education at elementary schools which was taught by Dance Forum Taipei. Students were asked to move along to musical rhythms and melodies so they could develop physical expression and perceptual capabilities, which helped them to trust their bodies and build their confidence for self-expression in a relaxed environment.



2025 Dance Forum Taipei Campus Creativity Outreach Program					
Service Target	Stakeholders	Number of Participants	Resources Invested	Activity Description	Achievements
Dongmen Elementary School, Zhongzheng District, Taipei City	- Taipei Performing Arts Center - Dance Forum Taipei - School teachers - Schoolchildren	- A total of 471 students participated in this program (including 20 students with special needs) 18 music and physical education teachers participated in this program - The total number of participants was 1,029 people	- PharmaEssentia provided a sponsorship of NT\$350,900 10 administrative personnel	1 instructor empowerment workshop - A total of 42 classes	- Student benefit ratio was 1:47.1 - Students developed concentration skills, emotional awareness, and the ability to empathize with others through this physical expression experience. - The teachers and students enjoyed the course immensely, and lower- and middle-grade teachers expressed interest in booking future classes.

Supplementary note:

- Equality in education: The course was open to students with special needs, who responded positively to instructor guidance, demonstrating that art can provide equitable means of expression.
- Teacher empowerment: A teacher workshop was held on June 25, 2025 for 18 music and physical education teachers.



Feedback from teachers: "The course was enthusiastically received by lower- and middle-grade students. We hope an enhanced version of this course can be offered again in the coming autumn"; "We expect there could be greater benefits if our school could first give us some background knowledge."

Feedback from Dance Forum Taipei: "Our biggest motivation stemmed from the children's natural physical coordination skills. We thank PharmaEssentia for helping us bring art into schools"; "Students with special needs also possess dancing abilities. They responded very well to our instructions, which encouraged us to continue developing course content."

3.Support for Domestic Cultural Development: Sponsoring Art Outreach Programs to Enhance Public Aesthetic Literacy

PharmaEssentia believes that corporate values stem from long-term social contributions. We therefore focused our social actions on culture and art, child education, charity initiatives, and social inclusion to promote educational equity, access to culture, and social resilience. We have long supported performance groups, arts and culture organizations, and artist exhibitions and performances. We also sponsored domestic films, music, and reading promotion activities, and collaborated with art galleries, museums, and local culture institutions to expand cultural participation and create sustained positive social impacts. In 2025, our total sponsorships exceeded NT\$3 million. Relevant activities are listed below and more information can be found at this [link](#).



No.	Sponsored Event	Event Description
1	Taipei Male Choir: Unbanned Songs, Unbowed Souls	Sponsorship amount: NT\$300,000
2	PaperWindmill Theatre: Saving Faust	Sponsorship amount: NT\$200,000
3	Taiwan Public Welfare League: 2025 Appreciation Concert	Sponsorship amount: NT\$200,000
4	All U People Theatre: Ximending District	Sponsorship description: Purchased 60 tickets amounting to NT\$169,150
5	Story Works: Tears On Fire The Musical	Sponsorship description: Purchased 100 tickets amounting to NT\$204,000
6	Give Meet Five: Three Unmarried Women Musical	Sponsorship description: Purchased 114 tickets amounting to NT\$250,100
7	National Taichung Theater Sponsorship	Sponsorship amount: NT\$500,000
8	One Song ORCHESTRA 2025 New Year Concert Sponsorship	Sponsorship amount: NT\$1,000,000
9	2025 Taiwan Music Festival	Sponsorship description: Purchased 50 tickets amounting to NT\$54,000
10	Private screening at Vieshow Cinemas: A Chip Odyssey	Sponsorship description: Purchased tickets and snacks amounting to NT\$126,320
11	2025 Taiwan Film Festival of Boston Sponsorship	Sponsorship amount: US\$1,000
12	Dance Forum Taipei: Campus Creativity Outreach Program Sponsorship	Sponsorship amount: NT\$350,900